
               
               
               CLINICAL PHARMACOLOGY:
               
               
                  
                     
                     
                     Microbiology:
                     
                        Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections:
                        
                           Streptococcus pyogenes(group A ÃŸ-hemolytic)
                        Alpha-hemolytic streptococci (viridans group)
                        
                           Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)
                        
                           Streptococcus pneumonia
                        
                        
                           Mycoplasma pneumoniae(Eaton Agent, PPLO)
                        
                           Haemophilusinfluenzae(not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)
                        
                           Treponemapallidum
                        
                        
                           Corynebacteriumdiphtheriae
                        
                        
                           Neisseria gonorrhoeae
                        
                        
                           Chlamydia trachomatis
                        
                     
                     
                  
               
            
         